Cara Therapeutics (NASDAQ:CARA) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued to investors on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

Shares of Cara Therapeutics stock opened at $0.34 on Tuesday. Cara Therapeutics has a 1 year low of $0.24 and a 1 year high of $1.31. The firm has a market cap of $18.64 million, a price-to-earnings ratio of -0.17 and a beta of 0.68. The company has a 50-day moving average of $0.29 and a 200 day moving average of $0.41.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The business had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. On average, equities analysts anticipate that Cara Therapeutics will post -1.24 EPS for the current year.

Hedge Funds Weigh In On Cara Therapeutics

An institutional investor recently bought a new position in Cara Therapeutics stock. Marquette Asset Management LLC acquired a new stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned about 0.17% of Cara Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.